Equity research analysts tracking Axsome Therapeutics, Inc. (NASDAQ: AXSM) predominantly issue positive ratings, with consensus views leaning heavily toward a buy recommendation. Wall Street analysts highlight strong commercial growth drivers—such as rising sales for its flagship depression medication Auvelity and pipeline expansions into Alzheimer's agitation—as major catalysts. While the company continues to record net losses while scaling commercial operations, robust revenue growth rates and high gross profit margins make it a favored growth stock among biotech investors.